UK Outlook 2018: All To Play For In Technology Adoption With AAR Set For Take Off
Executive Summary
Navigating the UK medtech innovation landscape is a notoriously complicated exercise, so industry is hoping the recently released Accelerated Access Review will have positive outcomes as 2018 unfolds. Andrew Davies, market access director for the Association of British Healthcare Industries, says a simplified system of market access for medtech would bring benefits across the board.
You may also be interested in...
Darzi Takes Witty's Seat At UK Innovation Group, As Brexit Heats Up And NHS Adds Ambiguity
The UK's Accelerated Access Collaborative (AAC) has filled the hole left by ex-Glaxo CEO Andrew Witty's recent departure with public-sector stalwart Lord Ara Darzi. This should restore some certainty to the initiative when the UK health-care sector was thrown into confusion by the promise of £20bn more NHS funding and by ongoing Brexit machinations with uncertain impact.
UK Outlook 2018: Medtech Readies For Change To FOM System Of Value-Based Procurement
For UK medtech companies, a new NHS value-based procurement system is coming in the shape of the Future Operating Model. ABHI COO Nishan Sunthares explains what the FOM will mean for UK medtechs when it applies fully later this year.
Revolutionary EU HTA Cooperation Proposal Will Use MDR/IVDR Platforms
The European Commission wants to rationalize health technology assessment work across the EU, and new EU medtech regulations offer an easy way to determine which products can benefit from joint clinical assessments.